Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety.
VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ...
Orthocell receives A$3.18 million R&D tax refund; brings war chest to A$33 million ...
VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech ...
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.
VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company&CloseCurlyDoubleQuote ...
VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife” or the "Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the ...
VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback